%0 Journal Article
%T Study of the Efficacy of Triple Therapy of Sofosbuvir, Pegylated INFalpha 2a and Ribavirin in Treatment of Chronic Hepatitis C Patients Genotype 4 with High Fibrosis
%A Alaa Aboud
%J Open Journal of Gastroenterology
%P 5-17
%@ 2163-9469
%D 2017
%I Scientific Research Publishing
%R 10.4236/ojgas.2017.71002
%X Purpose: The aim is<span style=\"font-family:\" color:red;\"=\"\"> </span><span style=\"font-family:;\" \"=\"\">evaluat</span><span style=\"font-family:;\" \"=\"\">ion</span><span style=\"font-family:;\" \"=\"\"> of the efficacy of </span><span style=\"font-family:;\" \"=\"\">t</span><span style=\"font-family:;\" \"=\"\">riple therapy of sofosbuvir, pegylated INFalpha 2a and ribavirin in
treatment of chronic hepatitis C (CHC) patients</span><span style=\"font-family:;\" \"=\"\"> </span><span style=\"font-family:;\" \"=\"\">genotype
4 who have high fibrosis. Materials and Methods: Fifty HCV patients with high
fibrosis (F3 &amp; F4) were included in the study. Results: SVR rate was 54%</span><span style=\"font-family:;\" \"=\"\">; </span><span style=\"font-family:;\" \"=\"\">non-responders rate was 12% and relapsers rate was
34%. When comparing SVR between F3 group patients and F4 group</span><span style=\"font-family:;\" \"=\"\">,</span><span style=\"font-family:;\" \"=\"\"> it was 88% and 66% respectively</span><span style=\"font-family:;\" \"=\"\">,</span><span style=\"font-family:;\" \"=\"\"> which means that SVR was
higher in the F3 group. Conclusion: Triple therapy including pegylated INFalpha
2a is not an ideal therapy in treatment of CHC patients genotype 4 with
cirrhosis because of low sustained virological response rates and high
incidence of side effects.</span>
%K Chronic Hepatitis C
%K Sofosbuvir
%K Pegylated INF
%K Ribavirin
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=73392